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ABSTRACT: A supramolecular strategy is presented for the
assembly of growth factors employing His6-tagged single-
domain antibodies (VHH). A combination of orthogonal
supramolecular interactions of β-cyclodextrin (βCD)−ada-
mantyl (Ad) host−guest and N-nitrilotriacetic acid (NTA)−
histidine (His) interactions was employed to generate
reversible and homogeneous layers of growth factors. A
single-domain antibody VHH fragment was identified to bind
to the human bone morphogenetic protein-6 (hBMP6) growth factor and could be recombinantly expressed in E. coli. The VHH
fragment was equipped with a C-terminal hexahistidine (His6) tether to facilitate the assembly on βCD surfaces using a linker
that contains an Ad group to bind to the βCD receptors and an NTA moiety to interact with the His6-tag upon cocomplexation
of Ni2+ ions. After exploring the thermodynamic and kinetic stability of the VHH assemblies on βCD surfaces using a variety of
experimental techniques including microcontact printing (μCP), surface plasmon resonance (SPR), microscale thermophoresis
(MST), and theoretical models for determining the thermodynamic behavior of the system, hBMP6 was assembled onto the
VHH-functionalized surfaces. After analyzing the immobilized hBMP6 using immunostaining, the biological activity of hBMP6
was demonstrated in cell differentiation experiments. Early osteogenic differentiation was analyzed in terms of alkaline
phosphatase (ALP) activity of KS483-4C3 mouse progenitor cells, and the results indicated that the reversibly immobilized
growth factors were functionally delivered to the cells. In conclusion, the supramolecular strategy used here offers the necessary
affinity, reversibility, and temporal control to promote biological function of the growth factors that were delivered by this
strategy.
Growth factors are considered major therapeutic agentsthat profoundly affect cell function.1−6 However, direct
bolus delivery or systemic administration of growth factors is of
limited clinical use as excessive dosing is required to detect a
measurable effect, which potentially could lead to off-target
effects.7 Correct localization and balance of growth factors can
be regulated by their encapsulation in carrier systems such as
hydrogels, scaffolds or layer-by-layer systems, which generally
sustain the spatial availability of growth factors facilitated by
their diffusion into tissue.8−21 An elegant strategy recently
reported by Maynard et al. relied on the stabilization of basic
fibroblast growth factors by covalent conjugation with a
heparin-mimicking polymer.22 Here we report the supra-
molecular capture of growth factors by using single monomeric
variable antibody fragments engineered from heavy chain
antibodies found in camelids (VHH fragments). Several
therapeutic applications employing VHH in cancer, infectious
and immune diseases have recently been reviewed.23−25 Unique
characteristics of VHH fragments such as their small size (12−
20 kDa), elevated stability in aqueous and even in organic
solvents and higher temperatures and reproducible recombi-
nant production make them promising candidates to explore
for activating surfaces in tissue regeneration. In addition,
selection of VHH binders to growth factors can be conveniently
done by means of phage display. VHHs are amenable for genetic
engineering allowing the site-specific introduction of reactive
groups, such as histidine tags, through which they can be site-
specifically immobilized to surfaces yielding homogeneously
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oriented layers of VHH fragments under physiological
conditions following supramolecular strategies.26,27
Supramolecular strategies, similar to bioresponsive covalent
linkages such as ester or thiol linkages, yield reversibility
providing a means to release growth factors and prompt a
biological function directly influenced by the desorption.
However, as opposed to such type of bioresponsive covalent
linkages, supramolecular delivery can be controlled by valency
and dissociation rate constants. Although supramolecular
chemistry has been successfully used to create biomimetic
systems,28−37 up to now, reports that show the potentialities of
supramolecular growth factor delivery systems predominantly
employ peptide fragments to allow for binding of growth
factors to supramolecular assemblies. For example, Stupp et al.
have bound transforming growth factor β-1 (TGF-β) to
oligopeptides that were displayed on the surface of self-
assembled nanotubular systems.38 Such supramolecular carrier
systems promoted chondrogenic differentiation of human
mesenchymal stem cells.38 Up to now, promising reports
exist on the use of supramolecular host−guest systems, such as
cyclodextrin and cucurbituril hosts, for the delivery of
transcription factors,39 for the release of peptides and
proteins,40−42 and to modulate cell adhesion;43−46 however,
yet no reports exist for their application as growth factor carrier
systems.11,28−30,47
We here present a supramolecular strategy to deliver growth
factors on β-cyclodextrin (βCD) surfaces using VHH as an
intermediate. The method requires simple assembly steps in
physiological conditions and offers the possibility to fine-tune
affinities and dissociation rate constants by molecular design.
We demonstrate the feasibility of our approach using human
bone morphogenetic protein 6 (hBMP-6) as a model growth
factor that is not recombinantly available and therefore cannot
be expressed with His-tags to allow for direct noncovalent
immobilization. hBMP-6 belongs to the TGF-β superfamily and
is known to play significant roles in cartilage and bone
morphogenesis and repair and is already used as a therapeutic
protein for inducing bone growth.48−50
■ RESULTS AND DISCUSSION
Design and Characterization of VHH Construct. VHH
clones that bind to hBMP-6 were selected following a phage
display approach (see the Supporting Information for details).
Affinity selection (biopanning) was carried out on hBMP-6
coated plates (0.2−5 μg/well), which were incubated with the
phage VHH immune library that was constructed after
immunization of llamas. After the second round, the relative
binding strength of selected phage VHH clones was assessed
against each other using an enzyme-linked immunosorbent
assay (ELISA) (see Supporting Information Figure S1a).
Subsequently, the strongest binding VHH clone was subcloned
in an expression vector with a C-terminal His-tag and
recombinantly produced in E. coli hosts. After purification
using affinity chromatography, a single band at 16 kDa was
detected by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (see Supporting Information
Figure S1b) in agreement with related VHH binders described
in literature.22−25
The interaction of the purified VHH construct with hBMP-6
was confirmed using microscale thermophoresis (MST) and
ELISA measurements. To determine the affinity between VHH
and hBMP-6 in solution, MST was used. A titration series of
hBMP-6 over a range of 0.04 nM to 0.7 μM was performed
while fluorescently labeled VHH was kept constant at 20 nM
throughout the series. Upon binding of hBMP-6, a change in
thermophoretic signal was observed as shown in Figure 1a.
Subsequent fitting of the data to a 1:1 binding model yielded
a dissociation constant Kd of 7.4 (±0.4) × 10
−8 M and
therefore Ka = 1/Kd = 1.4 × 10
7 M−1. These values are
comparable to the ones found in literature for VHH interactions
with different binding partners.22−25,51−53 The obtained affinity
was compared with affinity studies carried out in an ELISA
assay format. To the hBMP-6 coated microtiter plates, a series
of VHH solutions in the range of 0−3.3 μM was added and
assayed by ELISA (Figure 1b). After fitting the experimental
data to a Langmuir model, a Ka of 1.9 (±0.2) × 10
6 M−1 was
estimated, which is 1 order of magnitude lower than the affinity
measured by MST, which is a known effect when comparing
solution assays with array formats.26,27
Surface Assembly Analysis. With these VHH constructs
with high affinity toward hBMP-6 in hand, we sought to
employ the C-terminal His6-tag on the recombinantly produced
VHH for the assembly onto supramolecular βCD host surfaces
through specific interaction with adamantyl (Ad) guest
functionalized nitrilotriacetic acid (NTA) linkers.54−56 To
fabricate this supramolecular carrier system, a stepwise
assembly process (Scheme 1) was adopted using the
(NTA)−Ni(II)−His6-tag interaction and orthogonal linkers
consisting of three steps, that is, (1) preincubation of the βCD
surface with an ethylene glycol based monoadamantyl linker
(HEG-Ad) for minimizing the nonspecific protein adsorption,
(2) a solution of NTA-monoadamantyl linker (NTA-Ad) and
VHH in the presence of Ni(II) ions while maintaining the same
concentration of HEG-Ad, and (3) a solution of hBMP-6 was
used.39,40 Alternatively, after assembling HEG-Ad, a one-pot
assembly step with all components was performed (Scheme 1).
The assembly was performed at a physiological pH of 7.4,
which ensures complexation of Ni(II) ions to the majority of
the NTA moieties.50
Supramolecular βCD host monolayers on gold were placed
in an SPR flow cell.40 After the baseline became stable while
Figure 1. VHH binding to hBMP-6 analyzed (a) in solution by
microscale thermophoresis (MST) and (b) on microtiter plates by
ELISA (duplicate read-out).
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flowing PBS buffer, a solution of HEG-Ad (0.1 mM in PBS)
was flown for 10 min until a stable signal was observed (Figure
2a, triangles). Successively, a solution of 0.5 μM VHH·Ni(II)·
NTA-Ad (in a ratio of 1:5:5) in the presence of 0.1 mM HEG-
Ad was injected and flown continuously (0.1 mL min−1)
(Figure 2a, squares). The observed increase in the SPR signal
reached thermodynamic equilibrium after 10 min (Figure 2a,
spheres)). This observation indicates that VHH·(Ni(II)·NTA-
Ad)x (x = 1−3) species have replaced monovalent HEG-Ad,
confirming that higher valent adamantyl VHH·(Ni(II)·NTA-
Ad)x (x > 1) were preferentially interacting with the
supramolecular βCD host surface as determined by the
effective concentration (Ceff) (vide infra). To demonstrate the
reversibility of the assembly of VHH, a solution containing 10
mM of competing ligand EDTA and 10 mM of βCD in PBS
were added to the flow cell while monitoring the SPR response
(Figure 2a, circles). Although a sudden initial increase in the
SPR intensity was observed due to the large change in refractive
index when using a concentrated solution of EDTA and βCD,
the baseline was totally restored upon rinsing the system with
PBS for 5 min (Figure 2a, arrows). This result indicates the
complete disassembly of the molecules from the βCD surface.
To assess the thermodynamic stability of the VHH constructs at
the βCD surface, a titration series of VHH·Ni(II)·NTA-Ad
(1:5:5) in the range of 0.5−20 μM was performed while
recording the change in the SPR resonant angle. Between each
titration step, a disassembly cycle was performed to restore the
βCD surface as described above. Upon addition of HEG-Ad,
which represents the first step of the assembly of each titration
step, a constant increase in SPR intensity was observed (Figure
2a). The second step of the assembly was marked by a gradual
increase in the change of the SPR resonant angle saturating
above 20 μM of VHH (Figure 2).
The SPR data were satisfactorily fitted to a thermodynamic
model that accounts for all species possibly bound to the βCD
surface (Figure 2b; see the Supporting Information for details).
The model shows that, at low concentrations of VHH (<1 μM),
the major contribution to the (still low) SPR signal originates
from the assembly of monovalent HEG-Ad, while above 2 μM
VHH, when the coverage becomes appreciable, the major
contribution to the rise in SPR signal originates from trivalent
VHH·(Ni(II)·NTA-Ad)3 species (70%) as expected.
55 This
indicates that the trivalent complex is the main species
contributing to the coverage at the whole range of
concentrations until surface saturation (see Figure 2b and
Supporting Information Figure S2). Fixing the values of the
intrinsic binding constants Ki,HEG = 2.6 × 10
4 M−1 and Ki,NTA =
1.2 × 104 M−1 as found in literature,51 an association constant
K1 of 6.3 × 10
4 M−1, which represents the first interaction of
Ni(II)·NTA-Ad to the His6-tag, and a value for Ceff of 0.02 M
were found to fit the experimentally observed changes in SPR
resonant angle (Figure 2b). From these values, the second (K2)
and third (K3) association constants of the consecutive bonding
of His2-units to Ni(II)·NTA-Ad were calculated to be 1.5 × 10
4
and 1.95 × 103 M−1, respectively, in agreement with values
found in literature.50,57 The overall binding constant for the
trivalent complex on the βCD surface ([VHH] = 2 μM and
[Ni(II)·NTA-Ad] = 10 μM) was calculated to be in the order
of 106 M−1, in agreement with literature,58 and for the divalent
complex in the order of 105 M−1. In both cases, the multivalent
interactions lead to highly stable assemblies bound to the
surface while still being reversible.
Release of VHH Fragments. To visualize the release of the
VHH carrier system, fluorescence microscopy was used. To this
end, VHH was first fluorescently labeled with a Cy3-dye
following standard procedures (see the Supporting Informa-
tion). Cy3-VHH was used for patterning employing the well-
established microcontact printing (μCP) method with a
polydimethylsiloxane (PDMS) stamp.40,59 Such stamps were
inked for 2 min with a mixture of 1 μM Cy3-VHH/Ni(II)/
Scheme 1. Schematic Presentation of the Assembly of
hBMP-6 on Supramolecular βCD Host Surfacesa
aThe self-assembly follows either a stepwise (three steps) or one-pot
procedure. See text for details. Chemical structures of the building
blocks are given at the bottom.
Figure 2. (a) SPR data of a titration series of VHH·Ni(II)·NTA-Ad
(1:5:5) to βCD plates in the presence of 0.1 mM HEG-Ad. Symbols
indicate switching of the buffer to 0.1 mM HEG-Ad (▲), increasing
concentrations of VHH·Ni(II)·NTA-Ad (1:5:5; □→■) in the presence
of 0.1 mM HEG-Ad, 10 mM βCD/EDTA in PBS (●) and PBS (↓).
(b) Experimental change of SPR resonant angle (ΔΘ at thermody-
namic equilibrium; black markers) versus VHH concentration fitted to
the theoretical model (see Supporting Information). The contribution
of the assembly of the different molecules to the signal is given.
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NTA-Ad (1:5:5) in PBS buffer. After inking, the stamp was
blown dry and put into conformal contact with a supra-
molecular host glass surface for 5 min. After removing the
stamp, the slides were directly imaged. As a reference, the same
experiment was performed in which the PDMS stamp was
inked with a 1 μM solution of VHH without Ni(II)/NTA-Ad
added. In both cases, uniform dot patterns of 50 μm diameter
and spaced by 10 μm were clearly visible with an excellent
contrast with the background as imaged using fluorescence
microscopy (see Figure 3a and Supporting Information Figure
S3). After extensive rinsing for 30 min with PBS, the patterns
disappeared in the case of the reference experiment, which
lacked the supramolecular NTA-Ad linker, whereas clear
patterns remained visible in the case when NTA-Ad was
coprinted (see Supporting Information Figure S3). These
results indicate that the interactions between VHH and the
surface are governed by specific NTA·Ni(II)·His6-tag inter-
actions as envisioned. Subsequently, after washing the patterns
of the supramolecular VHH carrier system with a solution
containing 10 mM of βCD and EDTA, the patterns
disappeared (see Supporting Information Figure S3), which is
characteristic of reversible supramolecular interactions between
the protein and the surface. The observations made by
fluorescence microscopy suggest that homogeneous layers of
oriented VHH are fabricated as a result of specific and reversible
supramolecular interactions, in agreement with the SPR studies.
To acquire more information about the release of the VHH
fragments from the supramolecular VHH carrier system under
in vitro conditions, a series of substrates patterned with Cy3-
VHH·Ni(II)·NTA-Ad were immersed in cell culture medium
and four frames were recorded with a 0.2 s exposure time using
an inverted fluorescence microscope (Figure 3a−d). When
plotting the decay of the fluorescence intensity versus time
(Figure 3e), after 7 days around 80% of the fluorescence of the
Cy3-VHH disappeared from the βCD host surfaces. When the
data were fitted with first-order kinetics, a dissociation rate
constant of kd = ∼10−6 s−1 was found, which compares
favorably to an example in literature of immobilizing His6-
tagged proteins on covalently modified NTA surfaces.60
Growth Factor Assembly. The ability to extend the
release of VHH beyond days provides an interesting
opportunity to apply our supramolecular carrier system for
the delivery of growth factors to cells. To investigate whether
the VHH carrier system can be loaded with hBMP-6 growth
factors, patterns of dots of VHH were fabricated on glass slides
as described above and subsequently incubated with a solution
containing hBMP-6 (0.7 μM) for 1 h, according to the stepwise
approach (Scheme 1). After sequential coupling for 1 h of a
primary antibody (Ab) specific to hBMP-6 and a FITC-labeled
secondary Ab, the slides were imaged using fluorescence
microscopy. The recorded images show clearly that the
fluorescently labeled antibody was selectively immobilized on
the printed VHH patterns (Figure 4a). When surfaces were
blocked with BSA in addition to HEG-Ad prior to incubating
the slides with hBMP-6 and antibodies, the signal-to-noise was
enhanced. When the immunoassay was carried out on the VHH
patterns in the absence of hBMP-6, no fluorescent patterns
were observed (Figure 4b). Similar results were obtained when
the one-pot procedure was followed. When hBMP-6 loaded
surfaces were immersed in cell culture medium, inspection of
the surfaces using fluorescence microscopy showed that the
disappearance of the growth factor and VHH fragments
occurred in the same time window as compared to the VHH
only system. Presumably, the dissociation of our carrier system
relates to initial disruption of Ad/ βCD interactions (kd = 4 ×
10−3 s−1)61 and, once in solution, the multivalency of the VHH·
Ni(II)·(NTA-Ad)3 will be lost, followed by the eventual
dissociation of the growth factor from the VHH fragments. SPR
studies were also performed in the case of following the one-
pot assembly scheme. After recording a baseline by
continuously flowing a solution of 0.1 mM HEG-Ad, the flow
was switched to a solution of hBMP-6 in the presence of
different concentrations of VHH (and Ni(II)·NTA-Ad) while
monitoring the SPR intensity (Figure 4c). When a 50 nM
Figure 3. (a) Fluorescence microscopy image of Cy3-VHH patterned
by μCP on βCD glass slides recorded immediately after printing and
washing. Frames recorded with 0.2 s exposure time after immersion for
(b) 24 h, (c) 48 h, and (d) 168 h in cell culture medium. Scale bars
indicate 100 μm. (e) Release of Cy3-VHH is plotted relative to the
initial fluorescence intensity versus time. Inset shows the linear fitting
of the corresponding logarithmic values.
Figure 4. Fluorescence microscopy images after immunostaining the
patterned (dots of 100 μm in diameter and spaced by 20 μm)
supramolecular VHH carrier systems (a) loaded and (b) unloaded with
hBMP-6. Insets show a scheme representing each assembly. (c) SPR
sensograms of flowing VHH·Ni(II)·NTA-Ad with/without hBMP-6 as
indicated in the legend over a βCD slide. The solutions were premixed
for at least 30 min before injection (arrow) in the presence of 0.1 mM
of HEG-Ad.
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solution of hBMP-6 was used in the presence of a 2 μM
solution of VHH, an increase in the SPR resonant angle was
observed when compared to the case when a 2 μM solution of
VHH·Ni(II)·NTA-Ad was flown without hBMP-6 (Figure 4c,
short dashed versus dotted line). A similar observation was
made when using a 210 nM solution of hBMP-6 in the
presence of a 5 μM solution of VHH (Figure 4c, long-dashed
versus dot-dashed line). When a solution containing only
hBMP-6 was flown, no increase in the SPR intensity was
observed, indicating that nonspecific interactions between
hBMP-6 and the background surface are insignificant (Figure,
4c, straight line). These results confirm that hBMP-6 can
specifically be loaded onto the VHH carrier system, in
agreement with MST and ELISA studies, while in addition
hBMP-6 can be immuno-stained on the VHH carrier system,
presumably indicating that the active conformation of the
growth factor is maintained.
Cell Response. To explore the bioactivity of the supra-
molecularly loaded hBMP-6 surfaces, the induction of alkaline
phosphatase (ALP) was measured as early marker of osteogenic
differentiation of KS483 mouse progenitor cells.62,63 Cell line
KS483 is a mesenchymal precursor cell line that differentiates
into osteoblasts during a 1−3 week culture period when
cultured under osteogenesis-inducing conditions.62,63 While
mature human and mouse BMP-6 share 96% amino acid
identity and their cross reactivity with mouse and human BMP
receptors, the use of a murine cell line, such as KS483, is
suitable to assess the ability of hBMP-6 to initiate differ-
entiation into mineralizing osteoblasts.62,63 After cell culturing
on fully coated (nonpatterned) hBMP-6 surfaces for 7 days, a
live/dead assay showed negligible cytotoxicity (Figure 5c).
From a series of fully coated hBMP-6 surfaces and controls, the
ALP activity was measured and normalized to the DNA
content. Data is expressed as relative induction in comparison
to a bare glass substrates (Figure 5a) or to a layer of
immobilized VHH (Figure 5b). When hBMP-6 was loaded onto
the VHH carrier system in a step-by-step assembly process, the
ALP activity was 6-fold higher in comparison to the case when
VHH functionalized surfaces were used that lacked hBMP-6
(Figure 5a). In contrast, ALP activity was enhanced at best 2-
fold when soluble hBMP-6 was simply adsorbed to surfaces that
lack the VHH carrier system or glass only. No induction of ALP
activity was observed for the VHH carrier system without
hBMP-6. These results confirm that presenting hBMP-6
through VHH functionalized surfaces show the best differ-
entiation response as assessed by measuring ALP activity after 7
days of differentiation.61−63 This increase in differentiation
response could be attributed to the activity of hBMP-6 only.
When hBMP-6 was partly denatured at 95 °C after loading the
VHH carrier system, the ALP activity was significantly
decreased. An ELISA experiment was performed to determine
the amount of surface loaded hBMP-6 on the VHH carrier
system, which was prepared following the step-by-step
procedure. The released amount of hBMP-6 after 7 days was
determined to be 142 ± 17 ng. This result may give reason to
the higher ALP activity observed for hBMP-6 loaded surfaces
when compared with reference experiments on glass and on
substrates functionalized with VHH in which 100 ng of hBMP-6
was added to the cell culture medium. However, when cells
were seeded on hBMP-6 loaded surfaces that were prepared
following the one-pot assembly procedure using a solution of
100 ng of hBMP-6 and 0.5 μM VHH·Ni(II)·NTA-Ad (1:5:5), a
6-fold relative induction of the ALP production was observed
with respect to the case when hBMP-6 was left out of the
assembly solution to give VHH-only surfaces (Figure 5b). These
results show that irrespective of the assembly procedure,
biologically relevant amounts of hBMP-6 can be functionally
delivered to cells through the supramolecular VHH carrier
system.
■ CONCLUSION
We demonstrated that employing VHH fragments gives access
to capturing growth factors with high affinities while their
recombinant production is convenient and gives entry to
modification through genetic engineering. While VHH frag-
ments resemble human antibodies, immune response is
presumably negligible as opposed to other peptide sys-
tems.23−25 Our results show that, irrespective of the assembly
procedure, biologically relevant amounts of hBMP-6 can be
functionally loaded onto the supramolecular VHH carrier
Figure 5. ALP activity normalized by the total DNA content of KS483
cells after 7 days of culture, expressed as relative induction with respect
to (a) a glass control following a step-by-step assembly procedure or to
(b) a supramolecular VHH carrier system following a one-pot assembly
procedure. Notation on x-axis: “s” represents represents soluble
hBMP-6 supplemented to the cell medium; “b” represents hBMP-6
bound to the carrier system (fully coated) ; “db” represents hBMP-6
denatured at high temperature upon loading the carrier system (fully
coated). #p < 0.05 compared to VHH·Ni(II)·NTA-Ad,
##p < 0.01
compared to VHH·Ni(II)·NTA-Ad, and **p < 0.01 compared to all
cases. (c) Live−dead assay showing KS483 cells seeded on
supramolecular VHH carrier system loaded with hBMP-6 (fully
coated).
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system and successively delivered to cells. We show that growth
factors can be sequestered to the VHH carrier system, indicating
that locally excreted growth factors can possibly be bound to
the surface assisted by VHH. Introduction of supramolecular
coupling strategies offers additional opportunities to modulate
release profiles through variation of binding strengths40 and
dissociation rates or combination of supramolecular with
covalent strategies.65 Using oriented VHH fragments on
surfaces to carry growth factors provides a novel opportunity
to incorporate growth factors in various systems such as
hydrogels or scaffolds,45 and we believe that this will open new
ways to develop instructed biomaterials.
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